Skip to main content


Table 2 Response to treatment

From: Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Group (n) Treatment Complete pathological response (pCR) Outcome description
HER2+ [9] Paclitaxel Doxorubicin Cyclophosphamide and TZM 55,5% Five patients were alive with no evidence of disease recurrence; Three patients had disease recurrence; One patient deceased with disease progression (median follow-up 33.6 months)
HER2- [11] Paclitaxel Doxorubicin Cyclophosphamide 18% Four patients had systemic disease recurrence; one patient deceases with disease progression; two patients were under palliative care; seven patients lived with no evidence of disease recurrence (median follow-up 36.1 months)